The Journal of Pediatrics
Volume 156, Issue 1 , Pages 98-102.e1 , January 2010

Pubertal Metformin Therapy to Reduce Total, Visceral, and Hepatic Adiposity

  • Lourdes Ibáñez, MD, PhD

      Affiliations

    • Endocrinology, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, and CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Barcelona, Spain
    • Corresponding Author InformationReprint requests: Lourdes Ibáñez, MD, PhD, Endocrinology Unit, Hospital Sant Joan de Déu, University of Barcelona, Passeig de Sant Joan de Déu, 2, 08950 Esplugues, Barcelona, Spain.
    • ,
  • Abel Lopez-Bermejo, MD, PhD

      Affiliations

    • Pediatric Endocrinology, Dr. Trueta Hospital, Girona, Spain
    • ,
  • Marta Diaz, MD, PhD

      Affiliations

    • Endocrinology, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, and CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Barcelona, Spain
    • ,
  • Maria Victoria Marcos, MD, PhD

      Affiliations

    • Endocrinology Unit, Hospital de Terrassa, Terrassa, Spain
    • ,
  • Francis de Zegher, MD, PhD

      Affiliations

    • Department of Woman & Child, University of Leuven, Leuven, Belgium

Received 1 March 2009 ,Revised 10 June 2009 ,Accepted 6 July 2009.

References 

  1. Gluckman PD, Hanson MA, Cooper C, Thornburg KL. Effect of in utero and early-life conditions on adult health and disease. N Engl J Med. 2008;359:61–73
  2. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA. 2005;102:10604–10609
  3. Junien C, Nathanielsz P. Report on the IASO Stock Conference 2006: early and lifelong environmental epigenomic programming of metabolic syndrome, obesity and type II diabetes. Obes Rev. 2007;6:487–502
  4. Vigé A, Gallou-Kabani C, Junien C. Sexual dimorphism in non-Mendelian inheritance. Pediatr Res. 2008;63:340–347
  5. Dolinoy DC, Jirtle RL. Environmental epigenomics in human health and disease. Environ Mol Mutagen. 2008;49:4–8
  6. Ibáñez L, Suárez L, López-Bermejo A, Diaz M, Valls C, de Zegher F. Early development of visceral fat excess following spontaneous catch-up growth in children with low birthweight. J Clin Endocrinol Metab. 2008;93:925–928
  7. Ibáñez L, de Zegher F, Francois I, Potau N. Precocious pubarche, hyperinsulinism and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab. 1998;83:3558–3662
  8. Ibáñez L, Valls C, Potau N, Marcos MV, de Zegher F. Polycystic ovary syndrome after precocious pubarche: ontogeny of the low birthweight effect. Clin Endocrinol. 2001;55:667–672
  9. Ibáñez L, Ong K, de Zegher F, Marcos MV, del Rio L, Dunger D. Fat distribution in non-obese girls with and without precocious pubarche: central adiposity related to insulinemia and androgenemia from pre-puberty to post-menarche. Clin Endocrinol. 2003;58:372–379
  10. Ibáñez L, Ferrer A, Ong K, Amin R, Dunger D, de Zegher F. Insulin sensitization early post-menarche prevents progression from precocious pubarche to polycystic ovary syndrome. J Pediatr. 2004;144:23–29
  11. Ibáñez L, Jiménez R, de Zegher F. Early puberty-menarche after precocious pubarche: relation to prenatal growth. Pediatrics. 2006;117:117–121
  12. de Zegher F, Ibáñez L. Prenatal growth restraint followed by catch-up of weight: a hyperinsulinemic pathway to polycystic ovary syndrome. Fertil Steril. 2006;86(Suppl 1):S4–S5
  13. Ibáñez L, Jaramillo A, Enríquez G, Miró E, López-Bermejo A, Dunger DB, et al. Polycystic ovaries after precocious pubarche: relation to prenatal growth. Hum Reprod. 2007;22:395–400
  14. Ibáñez L, López-Bermejo A, Callejo J, Torres A, Cabré S, Dunger D, et al. Polycystic ovaries in non-obese adolescents and young women with ovarian androgen excess: relation to prenatal growth. J Clin Endocrinol Metab. 2008;93:196–199
  15. Reitman ML, Schadt EE. Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest. 2007;117:1226–1229
  16. Ibáñez L, Valls C, Marcos MV, Ong K, Dunger D, de Zegher F. Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin. J Clin Endocrinol Metab. 2004;89:4331–4337
  17. Ibáñez L, Ong K, Valls C, Marcos MV, Dunger DB, de Zegher F. Metformin treatment to prevent early puberty in girls with precocious pubarche. J Clin Endocrinol Metab. 2006;91:2888–2891
  18. Ibáñez L, López-Bermejo A, Diaz M, Marcos MV, de Zegher F. Metformin treatment for 4 years to reduce total and visceral fat in low-birthweight girls with precocious pubarche. J Clin Endocrinol Metab. 2008;93:1841–1845
  19. Koska J, Stefan N, Permana PA, Weyer C, Sonoda M, Bogardus C, et al. Increased fat accumulation in liver may link insulin resistance with subcutaneous abdominal adipocyte enlargement, visceral adiposity, and hypoadiponectinemia in obese individuals. Am J Clin Nutr. 2008;87:295–302
  20. Ibáñez L, Valls C, Ong K, Dunger D, de Zegher F. Metformin therapy during puberty delays menarche, prolongs pubertal growth, and augments adult height: a randomized study in low-birthweight girls with early-normal onset of puberty. J Clin Endocrinol Metab. 2006;91:2068–2073
  21. Ibáñez L, López-Bermejo A, Diaz M, Enríquez G, Valls C, de Zegher F. Pioglitazone (7.5 mg/d) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high-molecular-weight adiponectin. Clin Endocrinol (Oxf). 2008;68:317–320
  22. Ibáñez L, Sebastiani G, Diaz M, López-Bermejo A, Gómez-Roig MD, de Zegher F. Gender specificity of body adiposity and circulating adiponectin, visfatin, insulin and IGF-I at term birth: relation to prenatal growth. J Clin Endocrinol Metab. 2008;93:2774–2778
  23. Ibáñez L, Valls C, Ong K, Dunger D, de Zegher F. Early development of adiposity and insulin resistance following catch-up weight gain in low birth weight children. J Clin Endocrinol Metab. 2006;91:2153–2158
  24. Ong K, Potau N, Petry CJ, Ness AR, Jones R, Honour JW, et al. for the ALSPAC Study Team. Adrenarche is paradoxically modulated by prenatal and postnatal weight gain. J Clin Endocrinol Metab. 2004;89:2647–2651
  25. Ibáñez L, López-Bermejo A, Suárez L, Marcos MV, Diaz M, de Zegher F. Visceral adiposity without overweight in children born small-for-gestational-age. J Clin Endocrinol Metab. 2008;93:2079–2083
  26. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T. Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys Res Commun. 2008;375:414–419
  27. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130:456–469
  28. Lee NK, Karsenty G. Reciprocal regulation of bone and energy metabolism. Trends Endocrinol Metab. 2008;19:161–166
  29. La Marca A, Morgante G, Palumbo M, Cianci A, Petraglia F, De Leo V. Insulin-lowering treatment reduces aromatase activity in response to follicle-stimulating hormone in women with polycystic ovary syndrome. Fertil Steril. 2002;78:1234–1239
  30. Mansfield R, Galea R, Brincat M, Hole D, Mason H. Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril. 2003;79:956–962
  31. Tosca L, Chabrolle C, Uzbekova S, Dupont J. Effects of metformin on bovine granulosa cells steroidogenesis: possible involvement of adenosine 5′ monophosphate-activated protein kinase (AMPK). Biol Reprod. 2007;76:368–378
  32. Espetvedt Finstad S, Emaus A, Potischman N, Barrett E, Furberg AS, Ellison PT, et al. Influence of birth weight and adult body composition on 17β-estradiol levels in young women. Cancer Causes Control. 2009;20:233–242
  33. Ibáñez L, Potau N, Ferrer A, Rodriguez-Hierro F, Marcos MV, de Zegher F. Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism. J Clin Endocrinol Metab. 2002;87:5702–5705
  34. Ibáñez L, López-Bermejo A, de Zegher F. Pubertal adiposity after fetal growth restraint: toward a calorie restriction mimetic approach. Metabolism. 2008;57:672–675
  35. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics. 2001;107:E55
  36. Srinivasan S, Ambler GR, Baur LA, Garnett SP, Tepsa M, Yap F, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab. 2006;91:2074–2080
  37. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatr. 2006;163:2072–2079
  38. Atabek ME, Pirgon O. Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab. 2008;21:339–348
  39. Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr. 2008;152:817–822
  40. Burgert TS, Duran EJ, Goldberg-Gell R, Dziura J, Yeckel CW, Katz S, et al. Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatr Diabetes. 2008;9:567–576
  41. Casteels K, Fieuws S, van Helvoirt M, Verpoorten C, Goemans N, Coudyzer W, et al. Metformin therapy to reduce weight gain and visceral adiposity in children and adolescents with neurogenic or myogenic motor deficit. Pediatr Diabetes. 2009 May 28;[Epub ahead of print]

 L.I., M.D., and M.V.M. are Clinical Investigators of CIBERDEM (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Madrid, Spain). A.L.B. is an Investigator of the Fund for Scientific Research I3 (Ministry of Education and Science, Spain). F.dZ. is a Clinical Investigator of the Fund for Scientific Research (Flanders, Belgium).

 The authors declare no conflicts of interest.

PII: S0022-3476(09)00645-3

doi: 10.1016/j.jpeds.2009.07.012

The Journal of Pediatrics
Volume 156, Issue 1 , Pages 98-102.e1 , January 2010

Article Tools

* Image Usage & Resolution